$1.25 million awarded to progress University of Queensland-developed prostate cancer drug
Development of a new drug based on research at The University of Queensland, targeting advanced and therapy-resistant prostate cancer, has been awarded $1.25 million from the US-based Critical Path Institute’s Translational Therapeutics Accelerator. According to a statement from UQ on Tuesday, the drug named QED-203 has its origins in research by Professor Greg Monteith from…